Open Accessibility Menu

Coronavirus (COVID-19) Vaccine Update Click here to learn more.

For information about COVID-19 or to view additional resources, please click here.

Sun A Kim, MD,PhD,MS

GW Provider
Need an Appointment ?
This Provider Is Not Available For Appointments
Sun A Kim MD,PhD,MS Sun A Kim MD,PhD,MS

Specialties

Titles

  • Assistant Professor of Pathology
Medical Biography
Clinical Interests
  • Gastrointestinal pathology
  • Genitourinary pathology
  • Breast pathology
  • Autopsy
  • Digital pathology
  • Medical School
    • University of Ulsan College of Medicine
  • Residency
    • National Institutes of Health - Anatomic Pathology
  • Fellowship
    • Mount Sinai Medical Center - Surgical Pathology
    • Pennsylvania Hospital - Anatomic Pathology
Board Certified
  • Anatomic Pathology

Sun A Kim, MD, MS, PhD is a gastrointestinal, pancreas and hepatobiliary pathologist. Prior to joining GW, she completed a Gastrointestinal Pathology Fellowship at the Mount Sinai Medical Center in Manhattan, New York, a Surgical Pathology Fellowship at Pennsylvania Hospital, Philadelphia, PA, and Anatomic Pathology Residency at National Institutes of Health (NIH), Bethesda, MD, where she had the honor to hold a position of chief resident. She did a Research Fellowship in the Molecular Pathological Epidemiology Laboratory at the Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.  

Dr. Kim’s clinical practice focus is to provide pathology diagnosis of gastrointestinal tract, hepatobiliary-pancreatic diseases, and genitourinary system diseases. Dr. Kim provides expert pathology diagnostic services for the GW Department of Pathology and its consultation services (gwpathologyconsult@mfa.gwu.edu). 

Dr. Kim’s research is centered mainly on pathology and molecular characterization of digestive organ diseases. Dr. Kim participates in collaborative research in her areas of focus. Highlights of her research include: 

  1. Pathologic characterization and monitoring of pre- and post-treatment inflammatory bowel disease in association with immunotherapy.  
  2. Predictive molecular phenotype of colorectal cancers, particularly in relation with patient’s metabolic diseases, microbiome and modifiable lifestyle factors.
  3. Predictive markers and novel pathologic findings of pancreatic neoplasm including neuroendocrine tumors and solid pseudopapillary neoplasm. 

Locations